Pfizer
Compare Pfizer…Diversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
PfizerDiversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
Basic shares represent total shares issued. Diluted shares include potential shares from stock options, convertible securities, and other equity awards.
Q2 2016 — Q1 2026